DLL3 is highly expressed in 72% of primary SCLC tumor tissues and 85% of recurrent SCLC tumor tissues [267], whereas it is rarely expressed in normal tissues, making it a promising target [268, 269]. This evidence concerns the gene DLL3 and neoplasm.